Dihydroartemisinin represses oral squamous cell carcinoma progression through downregulating mitochondrial calcium uniporter

Shen Zheng, Ran Wu, Yunlong Deng, and Qiang Zhang

ABSTRACT
Dysregulation of mitochondrial calcium uniporter (MCU) exerts a carcinogenic effect in several cancers. Nevertheless, the roles of MCU in oral squamous cell carcinoma (OSCC) remain elusive. It has been reported that dihydroartemisinin (DHA) may suppress the progression of OSCC but its associated mechanisms have not been investigated. The purpose of our research was to observe the biological function of MCU on OSCC and its regulatory relationship with DHA. MCU, MCU1, MCU2, N-cadherin, TGF-β and vimentin expression was detected in OSCC and peritumoral tissues by immunohistochemistry and Western blot. Following DHA treatment, the expression of the aforementioned proteins was detected in CAL-27 cells transfected with shMCU or pcDNA3.1-MCU by Western blot or immunofluorescence. Furthermore, clone formation, mitochondrial membrane potential (MMP), wound healing and transwell assays were presented in CAL-27 cells treated with DHA, shMCU or pcDNA3.1-MCU. Our results showed that the members of MCU complex (MCU, MCU1 and MCU2) were overexpressed in OSCC than peritumoral tissues. Furthermore, TGF-β and epithelial to mesenchymal transition (EMT) proteins (N-cadherin and vimentin) exhibited higher expression in OSCC. DHA treatment significantly lowered the expression of MCU in CAL-27 cells. MCU overexpression reversed the inhibitory effects of DHA on MCU1, MCU2, N-cadherin, TGF-β and vimentin. MCU knockdown or DHA suppressed proliferation, MMP and migration of CAL-27 cells. DHA treatment could reverse the effects of MCU overexpression. Collectively, our study demonstrated that MCU was an oncogene of OSCC and DHA exerted a suppressive role on proliferation and migration of OSCC cells by suppressing MCU expression.

INTRODUCTION
Oral cancer, a malignant oral cavity neoplasm, occupies around 2% of all cancers [1]. Oral squamous cell carcinoma (OSCC) is the most frequently diagnosed type of oral cancer, representing 90% of all cases [2]. Smoking and drinking are the two main risk factors of OSCC [3]. Due to local recurrence and metastasis to lung, bone, liver, and mediastinal nodes, the five-year survival rate is only 50% [4]. Surgery is the main therapeutic strategy for patients at the early stage. Nevertheless, recurrence following surgery is the primary cause of death for OSCC patients [5]. Hence, developing innovative therapeutic strategies against OSCC has become an urgent priority. OSCC is a complex multifactorial and multistep process [6]. Various oncogenes and tumor suppressor genes may participate in OSCC progression [7]. Small molecules have been developed to target cancer-related proteins. Mitochondrial calcium uniporter (MCU) complex is a critical regulator in mitochondrial calcium (Ca^{2+}) homeostasis [8]. The MCU complex contains essential MCU regulator, MCU regulator 1, MCU-dominant-negative β-subunit (MCUb), mitochondrial calcium uptake (MICU)1, MICU2, and MICU3 [9,10]. MCU channel and its regulators transport calcium across the inner mitochondrial membrane to the mitochondrial matrix [11]. Several studies have confirmed the key roles and capacities of MCU complex on cellular behaviors and survival in cancers [12]. For example, loss of MCU has the suppressive roles on mitochondrial fusion in G1-S phase as well as blockage of cell cycle and survival [13]. MCU may enhance angiogenesis and promote breast cancer...
metastasis [14]. Also, it mediates the mitochondrial Ca\(^{2+}\) uptake and facilitates colorectal oncogenesis [15]. MCU-mediated mitochondrial Ca\(^{2+}\) promotes ROS production as well as metastasis of hepatocellular carcinoma cells by restraining NAD+/SIRT3/SOD2 pathway [16]. Recently, a study reported that MCU may be transcriptionally modulated by Nrf2, which triggers malignant biological behaviors in OSCC cells [17]. The specific mechanisms involving MCU remain unclear in OSCC.

Dihydroartemisinin (DHA), a semisynthetic derivative, is extracted from Artemisia annua [18]. Increasing evidences highlight the antitumor properties of DHA, including OSCC [18]. Chen et al. reported that DHA exerted inhibitory effects on invasion, migration, and angiogenesis of head and neck squamous cell carcinoma through prevention of M2 macrophage polarization and blockage of STAT3 phosphorylation [19]. Wang et al. found that DHA may prevent distant metastases of laryngeal cancer via inactivation of STAT3 in cancer stem cells [20]. Nevertheless, more experiments should be required to confirm the antitumor effects and targets of DHA in OSCC. This study aimed to investigate the biological functions of MCU on OSCC progression as well as the therapeutic effects and mechanisms of DHA in OSCC.

Materials and methods

Patients and specimens

Totally, 79 OSCC patients who underwent radical resection in North China University of Science and Technology Affiliated Hospital from January 2013 to August 2014 were randomly selected as the research objects. Inclusion criteria were as follows: (1) OSCC patients were confirmed by pathological examination, which met the criteria of WHO; (2) patients were first diagnosed as OSCC; (3) patients did not receive radiotherapy or chemotherapy. Exclusion criteria were as follows: (1) patients or family members did not agree to the observation; (2) patients had double primary cancers; (3) patients had congenital dysplasia. The peritumoral normal oral mucosa tissue more than 2 cm from the edge of the tumor was selected as a control. All the fresh tissues (freezing at –80 \(^{\circ}\)) and paraffin-embedded tissues were collected. The study was approved by the Ethics Committee of North China University of Science and Technology Affiliated Hospital (2013022), and informed consent form was signed with each patient.

Immunohistochemistry

The paraffin-embedded specimens were sliced serially, dried, deparaffinized, watered, followed by antigen retrieval through citric acid microwave. Then, the sections were incubated with 3% H\(_2\)O\(_2\) at room temperature for 30 min. The sections were washed with PBS and blocked with 5% BSA. The sections were treated with primary antibodies against MCU (1:100; sc-515,930; Santa Cruz, USA), MICU1 (1:100; ab190114; Abcam, USA), MICU2 (1:100; ab101465; Abcam, USA), TGF-β (1:100; sc-215715; Abcam, USA), N-cadherin (1:100; 22,018-1-AP; Proteintech, China) and vimentin (1:200; 10,366-1-AP; Proteintech, China) at 4°C overnight. After rinsing with PBS, the sections were dripped with HRP secondary antibodies (1:1000; ab6721; Abcam, USA) and incubated at room temperature for 2 h. The sections were developed by DAB and counterstained with hematoxylin. They were differentiated by 1% hydrochloric acid and ethanol, dehydrated, transparent, and mounted. The results of immunohistochemistry were judged by two pathologists under double blindness. Semi-quantitative analysis of staining results was performed based on the staining intensity and the percentage of positive cells. The staining intensity scores were divided into: 0 (no staining), 1 (light yellow), 2 (yellow), 3 (brown-yellow); the proportion of positive cells scores were as follows: 1 (0–10%), 2 (10–50%), 3 (50–100%). The final score was calculated as the staining intensity score × the proportion of positive cells score. Scores 1–3 were classified as negative, and scores ≥4 were classified as positive.

Western blot

The protein was extracted from tissues or cells. The BCA protein quantification kit was employed for quantitative detection of protein sample. The protein sample was added with 5× loading buffer,
mixed, and boiled at 100°C for 5 min. Each loading hole was filled with 40 μg protein sample. With 10% separating gel and 5% concentrated gel, electrophoresis was presented under the condition of 90 V constant pressure. The polyvinylidene fluoride (PVDF) membrane was soaked in the transfer buffer and protein was transferred to the membrane in an ice bath at 200 mA for 2 h. The membrane was placed in 5% bovine serum albumin and incubated at 37°C for 2 h. The membrane was incubated with primary antibodies against MCU (1:1000; sc-515,930; Santa Cruz, USA), MICU1 (1:1000; ab190114; Abcam, USA), MICU2 (1:1000; ab101465; Abcam, USA), N-cadherin (1:100; ab98952; Abcam, USA), TGF-β (1:1000; ab215715; Abcam, USA), vimentin (1:1000; 10,366-1-AP; Proteintech, China), Smad4 (1:1000; ab230815; Abcam, USA) and β-actin (1:2000; 20,536-1-AP, Proteintech, China) at 4°C overnight. After taking out the PVDF membrane, it was incubated with IgG secondary antibody (1:5000; ZB-2305; ZSGB-BIO, China) at room temperature for 2 h. After electrochemiluminescence, the image was captured for quantitative analysis with ImageJ.

**Cell culture**

TSCCa, FaDu and CAL-27 cells were purchased from Shanghai Zhongqiao Xinzhou Biological Technology Co., Ltd. (China). These cells were grown on the Minimum Essential Medium containing FBS, 1% P/S and 1% GlutaMax in an incubator of 5% CO₂ at 37°C.

**Transfection**

CAL-27 cells were inoculated into a 12-well plate (2 × 10⁵ cells/well). Starvation culture was performed with serum-free medium for 3 h before transfection. The shRNAs against MCU, pcDNA3.1-MCU, pcDNA3.1-TGFβ1 and the matched controls were transfected into CAL-27 cells. Lipofectamine™ 2000 transfection reagent (11668019; Thermo Fisher Scientific, USA) was applied according to the operating instructions. When cells were transfected for 48 h, Western blot was used to determine the MCU level.

**Cell Counting Kit-8 (CCK-8)**

CAL-27 cells were inoculated into a 96-well plate (1 × 10⁵ cells/well). After culturing for 24 h, cells were treated with different concentrations of DHA (0, 10, 20, 40, 60, 100 and 200 μM) and cultured for 48 h. 10 μL of CCK-8 solution (Dojindo, Japan) was added to each well and continued to incubate for 3 h. Finally, the absorbance was measured at 450 nm with a microplate reader.

**Flow cytometry**

CAL-27 cells were seeded in a 60-mm cell culture dish and incubated overnight. The cells were treated with different concentrations of DHA (0, 10, 20, 40, 60 and 100 μM). After 48 h of incubation, the cells were collected and stained with Annexin V-FITC/PI double staining kit. Flow cytometry was used to detect cell apoptosis.

**Immunofluorescence**

The transfected cells were fixed in 4% paraformaldehyde lasting 30 min. And, 0.5% Triton X-100 was applied to cover the slides and incubated at room temperature for 10 min. The sample was blocked with 10% goat serum for 1 h, and then washed thrice with 1% serum blocking solution. The primary antibody against MCU (1:100; sc-515,930; Santa Cruz, USA), MICU1 (1:1000; ab190114; Abcam, USA) and MICU2 (1:1000; ab101465; Abcam, USA) was added dropwise to the slices. After washing six times with 1% serum blocking solution, the sections were incubated with secondary antibodies Alexa Fluor® 488 Conjugate (1:100; ZF-0512; ZSGB-BIO, China) and Alexa Fluor® 594 Conjugate (1:100; ZF-0513; ZSGB-BIO, China) at room temperature for 2 h. Then, the sections were incubated by DAPI at room temperature for 5 min in the dark. The images were captured using an immunofluorescence microscope. The Image-Pro Plus 6.0 image
processing system was used to measure the average optical density of the protein.

**Clone formation assay**

Transfected CAL-27 cells were seeded in a six-well plate (5 × 10⁴/well) and placed in an incubator for culture. The culture medium was replaced every 24 h and continued to culture for 14 days. After washing with pre-cooled PBS, the cells were added with 500 μL of methanol and incubated at −20 for 20 min. Then, 400 μL 1% crystal violet staining solution was added to each well and incubated at room temperature for 15 min. After washing for 3 min, the number of cloned cells was counted.

**Mitochondrial membrane potential (MMP)**

CAL-27 cells were seeded onto a six-well plate (5 × 10⁵ cells/well) and transfected for 48 h. After washing with PBS, the cells were incubated with 1 mL medium working solution and 1 mL JC-1 staining working solution for 20 min at 37°C in a cell culture incubator. Then, the supernatant was aspirated. The sample was washed twice with JC-1 staining buffer (1×) and was added by 2 mL cell culture medium. The results were observed under a fluorescence microscope and analyzed using IPP 6.0 software.

**Wound healing assay**

First, two to three horizontal lines were drawn on the back of the six-well plate. CAL-27 cells were seeded onto the plate (6 × 10⁵ cells/well). After the cells were confluent, a 20-μL pipette tip perpendicular was used to scratch to the horizontal line. Then, the plate was washed with PBS and added serum-free medium. The images were captured under an inverted microscope at 0 h and 48 h, and analyzed with IPP 6.0 software.

**Transwell**

Transfected CAL-27 cells (6 × 10⁵ cells/well) were inoculated onto the upper chamber. Furthermore, culture medium was added to the lower chamber. Following culture for 24 h, migrated cells were fixed using 4% paraformaldehyde, followed by being stained using 0.1% crystal violet. Finally, the number of migrated cells was counted.

**Statistical analyses**

Statistical analyses were carried out using the GraphPad Prism v8.0 and SPSS v23.0 softwares. Data are expressed as mean ± standard deviation. Comparisons between groups were evaluated through Student’s t-test or one-way analysis of variance. Associations between MCU expression and clinicopathologic characteristics were analyzed via Chi-square test. p-Value <0.05 indicated statistical significance.

**Results**

Growing evidences reveal the carcinogenic role of MCU; however, the roles of MCU in OSCC are still unclear [12]. Furthermore, it has been reported that DHA has anti-OSCC properties but its associated mechanisms have been not investigated [18]. In this study, we observed the biological function of MCU on OSCC and its regulatory relationship with DHA.

**MCU is associated with clinicopathological characteristics of OSCC patients**

This study included 79 paired OSCC and peritumoral tissue specimens. Our immunohistochemistry showed the upregulation of MCU expression in OSCC compared to peritumoral tissues (Figure 1a, b). The relationships between MCU expression and clinicopathological characteristics of OSCC patients were evaluated in depth. As listed in Table 1, MCU expression exhibited significant correlations to depth of invasion, lymph metastasis, TNM stage, distant metastasis, and survival status in OSCC patients, indicating that MCU overexpression might participate in OSCC metastasis and survival outcomes. The regulators of MCU including MICU1 and MICU2 were detected in OSCC. As a result, there were higher levels of MICU1 and MICU2 in OSCC than peritumoral tissues.
TGF-β pathway is deregulated in several cancer types [21]. Higher TGF-β expression was found in OSCC than peritumoral tissues (Figure 1e). Epithelial-to-mesenchymal transition (EMT) is implicated in carcinogenesis [22]. EMT-related markers including N-cadherin and vimentin were detected in OSCC. The data showed their upregulation in OSCC than peritumoral tissues (figure 1f, g). Meanwhile, we detected the expression of MCU, MICU1, MICU2, TGF-β, and β-catenin proteins in seven paired OSCC and peritumoral tissues by Western blot (Figure 2a). Consistent with immunohistochemistry, higher expression of MCU (Figure 2b), MICU1 (Figure 2c), MICU2 (Figure 2d), TGF-β (Figure 2e), and β-catenin (Figure 2f) proteins was found in OSCC compared to peritumoral tissues.

**DHA may inhibit MCU expression in OSCC cells**

Western blot was employed to detect MCU expression in TSCCa, FaDu and CAL-27 cells. Among the three cell lines, MCU exhibited the
Table 1. Associations between MCU expression and clinicopathological characteristics in OSCC patients.

| Clinical parameters | Total (n = 79) | Positive (n = 57) | Negative (n = 22) | χ² | P-value |
|---------------------|---------------|------------------|------------------|----|---------|
| Age (years)         |               |                  |                  |    |         |
| <60                 | 41            | 31 (75.6%)       | 10 (24.4%)       | 0.507 | 0.476   |
| ≥60                 | 38            | 26 (68.4%)       | 12 (31.6%)       |    |         |
| Sex                 |               |                  |                  |    |         |
| Male                | 40            | 27 (67.5%)       | 13 (32.5%)       | 0.873 | 0.350   |
| Female              | 39            | 30 (76.9%)       | 9 (23.1%)        |    |         |
| Depth of invasion   |               |                  |                  |    |         |
| T1/T2               | 24            | 11 (45.8%)       | 13 (54.2%)       | 11.884 | 0.001   |
| T3/T4               | 55            | 46 (83.6%)       | 9 (16.4%)        |    |         |
| Lymph metastasis    |               |                  |                  |    |         |
| N0                  | 13            | 4 (30.8%)        | 9 (69.2%)        | 13.262 | <0.0001 |
| N1/N2/N3            | 66            | 53 (80.3%)       | 13 (19.7%)       |    |         |
| TNM stage           |               |                  |                  |    |         |
| I–II                | 22            | 12 (54.5%)       | 10 (45.5%)       | 4.704 | 0.030   |
| III–IV              | 57            | 45 (78.9%)       | 12 (21.1%)       |    |         |
| Distant metastasis  |               |                  |                  |    |         |
| Absent              | 27            | 14 (51.9%)       | 13 (48.1%)       | 8.413 | 0.004   |
| Present             | 52            | 43 (82.7%)       | 9 (17.3%)        |    |         |
| Survival            |               |                  |                  |    |         |
| Dead                | 32            | 15 (46.9%)       | 17 (53.1%)       | 17.103 | <0.0001 |
| Alive               | 47            | 42 (89.4%)       | 5 (10.6%)        |    |         |

TNM, tumor, nodule, metastasis.

highest expression in CAL-27 cells (Figure 3a, b). To observe the biological functions of MCU in OSCC, two shRNAs against MCU were transfected into CAL-27 cells. As a result, MCU expression was distinctly decreased following transfection with shMCU#2 (Figure 3c, d). Also, pcDNA3.1-MCU transfection significantly overexpressed MCU in CAL-27 cells (Figure 3e, f). CAL-27 cells were treated with different concentrations of DHA. CCK-8 results demonstrated that cell viability was gradually decreased as the concentration of DHA increased (Figure 3g). The IC50 value of DHA was 42.58 μM in CAL-27 cells following calculation. Also, apoptosis levels were gradually increased when DHA concentration elevated (Figure 3h). Finally, 40 μM DHA was selected as the optimal concentration. Western blot showed that MCU expression was distinctly lowered by DHA in CAL-27 cells (Figure 3i, j). Also, DHA treatment significantly decreased the expression of MICU1 and MICU2 in OSCC cells (Figure 3k, l). Furthermore, their expression was suppressed by MCU knockdown. In (Figure 3m, n) MCU exhibited higher expression under transfection with pcDNA3.1-MCU, which was decreased by DHA. However, pcDNA3.1-MCU transfection did not alter the expression of MCU in OSCC cells treated with DHA. Also, we found that the expression of MICU1 and MICU2 was lowered by DHA and overexpressed by pcDNA3.1-MCU in OSCC cells (Figure 3o, p). DHA treatment distinctly weakened the increase in MICU1 and MICU2 expression caused by pcDNA3.1-MCU. The above data demonstrated that DHA may lower MCU expression in OSCC cells.

**DHA suppresses TGF-β and EMT pathways in OSCC cells by targeting MCU**

We also evaluated whether DHA suppressed TGF-β and EMT pathways in OSCC cells via targeting MCU. Our Western blot demonstrated that the expression of TGF-β and EMT-related proteins including N-cadherin, TWIST, vimentin, and β-catenin was significantly decreased in CAL-27 cells under treatment with DHA or MCU knockdown (Figure 4a-f). Also, we found that the expression of TGF-β, N-cadherin, TWIST, vimentin, and β-catenin proteins was distinctly elevated by MCU overexpression in CAL-27 cells, which was weakened by DHA treatment (Figure 4g-l).
MCU activates TGF-β/Smad4 pathway in OSCC cells

Our Western blot demonstrated that TGF-β was significantly overexpressed in CAL-27 cells transfected with pcDNA3.1-TGF-β (Figure 4m, n). MCU knockdown weakened the overexpression of TGF-β in CAL-27 cells. Furthermore, Smad4 expression was decreased by pcDNA3.1-TGF-β and this inhibitory effect was enhanced by MCU overexpression (Figure 4o). The above data indicated that MCU may enhance TGF-β/Smad pathway in OSCC cells.

DHA suppresses MCU and its regulators in OSCC cells

Immunofluorescence assessed the effects of DHA on MCU and its regulators in OSCC (Figure 5a). As expected, MCU expression was distinctly lowered by
Figure 3. DHA may inhibit MCU and its regulators expression in OSCC cells. (a, b) Western blot detecting MCU expression in three OSCC cell lines: TSCCa, FaDu and CAL-27. (c, d) Western blot for the expression of MCU in CAL-27 cells transfected with shMCU. (e, f) Western blot for MCU expression in CAL-27 cells following transfection with pcDNA3.1-MCU. (g) CCK-8 of the cell viability of CAL-27 cells treated with different concentrations of DHA. (h) Flow cytometry of the apoptotic levels of CAL-27 cells under treatment with different concentrations of DHA. (i–l) Western blot for detecting the expression of MCU, MICU1 and MICU2 proteins in CAL-27 cells treated with DHA and/or shMCU. (m–p) Western blot for detecting the expression of MCU, MICU1 and MICU2 proteins in CAL-27 cells after treatment with DHA and/or pcDNA3.1-MCU. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: not significant.
shMCU transfection or DHA treatment and its expression was enhanced by pcDNA3.1-MCU transfection in CAL-27 cells (Figure 5b). Also, DHA treatment could reverse the increase in MCU expression induced by pcDNA3.1-MCU. Furthermore, we detected the expression of MICU1 and MICU2 in CAL-27 cells. As a result, shMCU transfection or DHA treatment significantly decreased MICU1 and MICU2 expression (Figure 5c, d). Inversely, their expression was significantly increased by pcDNA3.1-MCU. However, DHA treatment could reverse the increase in MICU1 and MICU2 expression induced by pcDNA3.1-MCU transfection.

**Figure 4.** DHA suppresses TGF-β and EMT pathways in OSCC cells by MCU. (a–f) Western blot for detecting the expression of N-cadherin, TGF-β, TWIST, vimentin and β-catenin proteins in CAL-27 cells treated with DHA and/or shMCU. (g–l) Western blot for the expression of N-cadherin, TGF-β, TWIST, vimentin and β-catenin proteins in CAL-27 cells treated with DHA and/or pcDNA3.1-MCU. (m–o) Western blot for the expression of Smad4 and TGF-β proteins in CAL-27 cells transfected with pcDNA3.1-TGF-β1, shMCU and/or pcDNA3.1-MCU. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: not significant.
expression caused by pcDNA3.1-MCU. Thus, our findings demonstrated that DHA exerted a suppressive role on MCU complex in OSCC cells.

**DHA restrains proliferation and MMP by reducing MCU expression in OSCC cells**

Clone formation assay was presented for determining the proliferation ability of OSCC cells. Our data showed that the number of cloned CAL-27 cells was significantly lowered by shMCU and elevated by pcDNA3.1-MCU (Figure 6a, b). Thus, MCU could enhance the proliferative ability of OSCC cells. Following DHA treatment, there was a decrease in the number of cloned cells, indicating that the proliferative capacity could be restrained by DNA treatment. Also, DHA distinctly weakened the increase in the number of cloned cells induced by pcDNA3.1-MCU. Nevertheless, pcDNA3.1-MCU did not alter the effects of DHA on clone formation ability. These data were indicative that DHA exerted a suppressive effect on proliferation of OSCC cells by targeting MCU. Our results showed that MMP levels were significantly reduced by shMCU and increased by pcDNA3.1-MCU, indicating that MCU activated MMP levels in OSCC cells (Figure 6c, d). Moreover, increased MMP levels were found in CAL-27 cells following treatment with DHA. DHA distinctly weakened the increase in MMP levels induced by pcDNA3.1-MCU in CAL-27 cells. However,

![Immunofluorescence for detecting the expression of MCU, MICU1 and MICU2 proteins in OSCC cells.](image-url)

**Figure 5.** Immunofluorescence for detecting the expression of MCU, MICU1 and MICU2 proteins in OSCC cells. (a) Representative images of immunofluorescence of MCU, MICU1 and MICU2 proteins in OSCC cells following treatment with shMCU, pcDNA3.1-MCU or DHA. (b–d) Quantification results of the expression of (b) MCU; (c) MICU1; and (d) MICU2 in OSCC cells following treatment with shMCU, pcDNA3.1-MCU or DHA. Bar = 20 μm. ***p < 0.001; ****p < 0.0001.
pcDNA3.1-MCU did not affect the inhibitory roles of DHA on MMP. Thus, DHA could suppress MMP levels by restraining MCU expression in OSCC cells.

**DHA inhibits migration of OSCC cells by lowering MCU expression**

Migrated capacity of OSCC cells was evaluated by wound healing and transwell assays. In Figure 7a, b our data showed that wound distance was significantly broadened by shMCU and shortened by pcDNA3.1-MCU in CAL-27 cells. The wider wound distance was detected in CAL-27 cells treated with DHA. Moreover, DHA treatment weakened the suppressive effect of pcDNA3.1-MCU on migrated ability. On the contrary, the decrease in migrated ability caused by DHA was ameliorated by pcDNA3.1-MCU transfection in CAL-27 cells. Transwell assay was also presented and the number of migrated CAL-27 cells was determined. As a result, the number of migrated CAL-27 cells was decreased by shMCU or DHA treatment (Figure 7c, d). Also, pcDNA3.1-MCU increased the number of migrated CAL-27 cells, which was weakened by DHA treatment. Meanwhile, MCU overexpression distinctly ameliorated the decrease in the number of migrated cells caused by DHA.

**Discussion**

With the continuous research on the pathogenesis of OSCC, gene targeted therapy has become a new treatment method [23–25]. This study observed the upregulation of MCU and its regulators in

![Figure 6](image_url)

**Figure 6.** DHA exerts an inhibitory effect on proliferation and MMP by decreasing MCU expression in OSCC cells. (a, b) Clone formation assay for detecting the number of cloned CAL-27 cells under treatment with DHA or transfection with shMCU or pcDNA3.1-MCU. (c, d) Mitochondrial membrane potential of CAL-27 cells treated with DHA or transfected with shMCU or pcDNA3.1-MCU. Bar = 20 μm.**p < 0.01; ***p < 0.001; ****p < 0.0001.
OSCC tissues. Our results demonstrated that MCU overexpression promoted proliferation, MMP and migration of OSCC cells. DHA could lower MCU expression in OSCC. Additionally, DHA exerted a suppressive role on OSCC progression by targeting MCU. Taken together, our study provided novel insights into OSCC pathogenesis as well as therapeutic strategies.

Among 79 OSCC patients, MCU expression was in relation to depth of invasion, lymph metastasis, TNM stage, distant metastasis, and survival status. Our data were indicative that MCU upregulation contributed to undesirable clinical outcomes of OSCC patients. Previously, MCU expression was correlated to poor prognosis and metastasis of colon cancer [26], hepatocellular carcinoma [27] and the like. Our further analysis found that MCU upregulation promoted proliferation of OSCC cells. Cancer cells exhibit excellent adaptive and robust capacities for survival, metastasis, and resistance by relying on various cellular processes, some of which involve mitochondrial activity [12]. Here, MCU overexpression could elevate MMP levels and facilitate migration in OSCC cells. The implications of MCU in predicting prognosis require to be verified in a larger OSCC population.

**Figure 7.** DHA lowers migration of OSCC cells by suppressing MCU expression. (a, b) Wound healing assay for determining the wound distance in CAL-27 cells treated with DHA or transfected with shMCU or pcDNA3.1-MCU. Bar = 200 μm. (c, d) Transwell assay for the number of migrated CAL-27 cells under treatment with DHA or transfection with shMCU or pcDNA3.1-MCU. Bar = 50 μm. *p < 0.05; **p < 0.01; ****p < 0.0001.
cohort. The regulators of MCU including MICU1 and MICU2, mitochondrial inner membrane proteins, were overexpressed in OSCC compared to peritumoral tissues. Their elevation has been detected in various cancers [28]. Our data indicated that MICU1 and MICU2 overexpression might be in relation to OSCC progression. Consistent with previous research, higher TGF-β expression was found in OSCC than peritumoral tissues [29]. Its upregulation may be induced by various molecules like IncRNA PAPAS [30]. Targeting TGF-β pathway may overcome gemcitabine resistance and restrain progression of OSCC [31]. Our data showed that MCU overexpression could enhance TGF-β pathway activation in OSCC cells. Tumor metastasis is an important cause of tumor death. EMT is the basis of tumor metastasis and an important reason for tumor cells to gain metastasis [32]. It is implicated in OSCC progression as well as metastasis [33]. Here, overexpressed N-cadherin and vimentin were found in OSCC tissues. In vitro, their upregulation could be induced by MCU overexpression, indicating that MCU participated in OSCC progression by activating EMT process.

The anti-OSCC roles of DHA have been found by different pathways in several studies [19]. For example, DHA treatment may suppress development and metastases of OSCC via suppression of macrophage polarization in tumor microenvironment [19]. Furthermore, DHA may suppress tumor growth of OSCC via targeting Jak2/STAT3 pathway [34]. It prevents distant metastases of laryngeal carcinoma via inactivation of STAT3 [20]. Our data showed that DHA could lower MCU expression in OSCC cells. Also, it inhibited proliferation, MMP, migration, EMT process and TGF-β pathway by restraining MCU expression in OSCC cells. These findings demonstrated that DHA exerted the anti-OSCC effects by targeting MCU expression, which would be verified in vivo assays.

**Conclusion**

Our data demonstrated that MCU may facilitate OSCC progression by enhancing proliferation, MMP and migration. This indicated that MCU potentially became a novel therapeutic target against OSCC. Furthermore, its expression was restrained by DHA. DHA possessed anti-OSCC properties through targeting MCU. Collectively, our findings confirmed the anti-OSCC effect of DHA and its associated mechanisms.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was funded by Medical Science Research Project Plan of Hebei Health Commission (20210223); Hebei Provincial Higher Education Basic Research Funds (JQN2020012).

**Availability of Data and Material**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

Qiang Zhang conceived and designed the study. Shen Zheng and Ran Wu conducted most of the experiments and data analysis, and wrote the manuscript. Yunlong Deng participated in collecting data and helped to draft the manuscript. All authors reviewed and approved the manuscript.

**Ethics approval and consent to participate**

The study was approved by the Ethics Committee of North China University of Science and Technology Affiliated Hospital (2013022).

**Consent for publication**

All patients provided written informed consent.

**ORCID**

Qiang Zhang [http://orcid.org/0000-0002-0248-1317](http://orcid.org/0000-0002-0248-1317)

**References**

[1] Dan H, Liu S, Liu J, et al. RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-κB pathway in oral squamous cell carcinoma. Mol Oncol. 2020;14(4):795–807.
[2] Lu Y, Zheng Z, Yuan Y, et al. The emerging role of exosomes in oral squamous cell carcinoma. Front Cell Dev Biol. 2021;9:628103.

[3] Zhang L, Meng X, Zhu XW, et al. Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications. Mol Cancer. 2019;18(1):102.

[4] Weiße J, Rosemann J, Krauspe V, et al. RNA-binding proteins as regulators of migration, invasion and metastasis in oral squamous cell carcinoma. Int J Mol Sci. 2020;21:6835.

[5] Weckx A, Riekert M, Grandoch A, et al. Time to recurrence and patient survival in recurrent oral squamous cell carcinoma. Oral Oncol. 2019;94:8–13.

[6] Huang F, Xin C, Lei K, et al. Noncoding RNAs in oral premalignant disorders and oral squamous cell carcinoma. Cell Oncol (Dordr). 2020;43(5):763–777.

[7] Yang Y, Chen D, Liu H, et al. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019;10(2):41.

[8] Liu Y, Jin M, Wang Y, et al. MCU-induced mitochondrial calcium uptake promotes mitochondrial biogenesis and colorectal cancer growth. Signal Transduct Target Ther. 2020;5(1):59.

[9] Delierneux C, Koub A, Shankupriya S, et al. Mitochondrial calcium regulation of redox signaling in cancer. Cells. 2020;9(2):432.

[10] Woods JJ, Wilson JJ. Inhibitors of the mitochondrial calcium uniporter for the treatment of disease. Curr Opin Chem Biol. 2020;55:9–18.

[11] Cui C, Yang J, Fu L, et al. Progress in understanding mitochondrial calcium uniporter complex-mediated calcium signalling: a potential target for cancer treatment. Br J Pharmacol. 2019;176(9):1190–1205.

[12] Vultur A, Gibhardt CS, Stanisz H, et al. The role of the mitochondrial calcium uniporter (MCU) complex in cancer. Pflugers Arch. 2018;470(8):1149–1163.

[13] Koval OM, Nguyen EK, Santhanah V, et al. Loss of MCU prevents mitochondrial fusion in G(1)-S phase and blocks cell cycle progression and proliferation. Sci Signal. 2019;12(579):eaav1439.

[14] Zheng X, Lu S, He Z, et al. MCU-dependent negative sorting of miR-4488 to extracellular vesicles enhances angiogenesis and promotes breast cancer metastatic colonization. Oncogene. 2020;39(46):6975–6989.

[15] Zeng F, Chen X, Cui W, et al. RIPK1 binds MCU to mediate induction of mitochondrial Ca(2+) uptake and promotes colorectal oncogenesis. Cancer Res. 2018;78:2876–2885.

[16] Ren T, Zhang H, Wang J, et al. MCU-dependent mitochondrial Ca(2+) inhibits NAD(+) /SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells. Oncogene. 2017;36(42):5897–5909.

[17] Wu R, Zuo W, Xu X, et al. MCU that is transcriptionally regulated by Nrf2 augments malignant biological behaviors in oral squamous cell carcinoma cells. Biomed Res Int. 2021;2021:6650791.

[18] Chaib I, Cai X, Llge D, et al. Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. Ann Transl Med. 2019;7(22):651.

[19] Chen R, Lu X, Li Z, et al. Dihydroartemisinin prevents progression and metastasis of head and neck squamous cell carcinoma by inhibiting polarization of macrophages in tumor microenvironment. Onco Targets Ther. 2020;13:3375–3387.

[20] Wang W, Sun Y, Li X, et al. Dihydroartemisinin prevents distant metastasis of laryngeal carcinoma by Inactivating STAT3 in cancer stem cells. Med Sci Monit. 2020;26:e922348.

[21] Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3:56–71.

[22] Zhu X, Chen L, Liu L, et al. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044.

[23] Chai AWY, Lim KP, Cheong SC. Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2020;61:71–83.

[24] Prat A, Navarro A, Paré L, et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 2017;77:3540–3550.

[25] Solomon B, Young RJ, Risichin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52:228–240.

[26] Sun Y, Li M, Liu G, et al. The function of Piezol in colon cancer metastasis and its potential regulatory mechanism. J Cancer Res Clin Oncol. 2020;146(5):1139–1152.

[27] Li CJ, Lin HY, Ko CJ, et al. A novel biomarker driving poor-prognosis liver cancer: overexpression of the mitochondrial calcium gatekeepers. Biomedicines. 2020;9(1):8.

[28] Rao G, Dwivedi SKD, Zhang Y, et al. MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020;21:e48483.

[29] Wang Y, Jia RZ, Diao S, et al. miRNA-101 targets TGF-βRI to retard the progression of oral squamous cell carcinoma. Oncol Res. 2020;28:203–212.

[30] Zhang P, Liu Y, Li C, et al. LncRNA PAPAS promotes oral squamous cell carcinoma by upregulating transforming growth factor-β1. J Cell Biochem. 2019;120(9):16120–16127.
[31] Xuan YZ, Jin CR, Yang KJ. TGF-β downregulation overcomes gemcitabine resistance in oral squamous cell carcinoma. Cancer Biomark. 2020;29:179–187.

[32] Parikh AS, Puram SV, Faquin WC, et al. Immunohistochemical quantification of partial-EMT in oral cavity squamous cell carcinoma primary tumors is associated with nodal metastasis. Oral Oncol. 2019;99:104458.

[33] Bai Y, Sha J, Kanno T. The role of carcinogenesis-related biomarkers in the Wnt pathway and their effects on Epithelial-Mesenchymal Transition (EMT) in oral squamous cell carcinoma. Cancers (Basel). 2020;12(3):555.

[34] Jia L, Song Q, Zhou C, et al. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling. PLoS One. 2016;11(1):e0147157.